PDCD1LG2 and neoplasm: On the other hand, nivolumab is a fully human IgG-4 PD-1 ICI antibody that selectively blocks the interaction between PD-1, which is expressed on activated T cells, and its ligands PD-L1 and PD-L2, which are expressed on immune cells and tumor cells.